Nkarta Inc (US:NKTX) — Company Overview, News & Financial Data
Nkarta Inc develops innovative NK cell therapies for hematologic cancers and solid tumors.
Nkarta Inc
Nkarta (NASDAQ:NKTX) specializes in the development of cancer therapies through innovative natural killer (NK) cell engineering and manufacturing technologies. They are at the forefront of advancing NK cell therapy, aiming to provide new treatment options for patients suffering from various hematologic cancers and solid tumors. Their projects are structured around harnessing and enhancing the innate power of NK cells to target and kill cancerous cells more effectively. Nkarta's objective is to revolutionize cancer treatment by developing therapies that offer a significant clinical benefit to patients, focusing on both safety and efficacy. Their research and development efforts are dedicated to bringing groundbreaking NK cell therapies from the laboratory to the clinic, striving to make a substantial impact on how cancer is treated.
Snapshot
Operations
Products and/or services of Nkarta Inc
- NKX101, a novel engineered natural killer (NK) cell therapy targeting NKG2D ligands on cancer cells for hematological malignancies and solid tumors.
- NKX019, a CAR NK cell therapy aimed at B cell malignancies through targeting CD19.
- A collaboration with CRISPR Therapeutics to develop CAR NK cell therapies, enhancing cancer treatment efficacy.
- NKX034, designed for HER2-overexpressing tumors, leveraging HER2-specific CAR NK cell technology.
- Partnership with Vertex Pharmaceuticals to advance cell therapies for cancer, focusing on novel engineered NK cell treatments.
- Co-development with Sana Biotechnology on engineered NK and T cell therapy projects for broader therapeutic applications.
Nkarta Inc executive team
- Mr. Paul J. HastingsCEO & Director
- Dr. Nadir Mahmood Ph.D.President and Principal Accounting & Financial Officer
- Dr. Shawn Rose M.D., Ph.D.Chief Medical Officer and Head of Research & Development